文献速递泌尿生殖MRUS

区级综合医院前列腺多参数MRI的PI-RADS评分:PI-RADS 3结果与组织学发现的关联

Multiparametric MRI prostate PI-RAD scoring in a district general hospital: correlating PI-RADS 3 results with histological findings.
PubMed 文献 · Br J Radiol · 2022-01-05

该回顾性研究纳入143例连续接受前列腺多参数MRI并给出PI-RADS评分的患者,其中45例为PI-RADS 3病变,32例随后行超声引导下活检;活检者中43%组织学证实为恶性前列腺腺癌,56%为非恶性;恶性者中位PSA更高、平均前列腺体积更小;结论认为PI-RADS 3不能准确区分良恶性病变。

要点

  • PI-RADS 3病变活检者中43%为恶性前列腺腺癌,56%为非恶性。
  • 恶性PI-RADS 3病变的中位PSA更高、平均前列腺体积更小。
  • PI-RADS 3不能准确区分良恶性,超声引导下活检对鉴别仍至关重要。

核心结论

  • 研究证实PI-RADS 3评分不能准确区分恶性与非恶性病变,需超声引导下前列腺活检及PSA参数进一步明确病变性质。
  • 对于PI-RADS 3患者,超声引导下前列腺活检在区分恶性与非恶性病变中仍至关重要。
  • 需要多中心PI-RADS 3的MRI数据以获得足够样本量进行统计分析。

研究设计与样本

  • 回顾性队列研究,纳入143例连续患者,每例均行前列腺多参数MRI并给出PI-RADS评分。
  • 共识别45例PI-RADS 3病变患者,其中32例随后接受经直肠/经会阴超声引导下活检。
  • 以组织学为参考标准,将PI-RADS 3病变分为恶性与非恶性,并分析PSA结果与前列腺体积。

诊断标准与关键数值

  • PI-RADS 3定义为「可疑」前列腺癌存在,不能自信确定是否存在显著前列腺疾病。
  • 45例PI-RADS 3患者中32例行活检,其中43%组织学证实为恶性前列腺腺癌,56%为非恶性。
  • 恶性病变组中位PSA更高、平均前列腺体积更小。

临床应用与阅片要点

  • PI-RADS 3病变不能准确区分良恶性,阅片报告时应结合PSA参数提示进一步评估。
  • 超声引导下前列腺活检对PI-RADS 3病变的良恶性鉴别仍至关重要。

局限性

  • 原文指出需要多中心PI-RADS 3的MRI数据以获得足够样本量进行统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Prostate cancer is the most common male cancer in the UK. In many hospitals, patients are now being referred for a multiparametric (mp) MRI scan of their prostate as part of an evaluation for the presence of prostate cancer, prior to an ultrasound-guided biopsy. Prostate Imaging Reporting and Data System (PI-RADS) score of 3 are defined as "equivocal" for the presence of prostate cancer. Thus, a PI-RADS 3 lesion does not confidently determine whether there is significant prostate disease or not.Our aim is to determine the correlation of PI-RADS 3 prostatic lesions with histology proven, clinically significant cancer.

METHODS: We performed a retrospective review on a cohort of 143 consecutive patients. Each patient underwent a mp-MRI scan of their prostate given a PI-RADS score. PI-RADS 3 lesions were analysed further based on histology and categorised into malignant and non-malignant lesions. Prostate-specific antigen (PSA) results and prostatic volume of PI-RADS 3 lesions were also analysed.

RESULTS: We identified 45 patients with PI-RADS 3 lesions out of 143 patients. 32 patients subsequently underwent transrectal/transperineal ultrasound-guided biopsy. 43% of patients were found to have had a malignant prostatic adenocarcinoma on histology. The remaining 56% had non-malignant findings. Of those with malignant disease, there was a higher median PSA and lower mean prostatic volume.

CONCLUSION: The study confirms that a score of PI-RADS 3 does not accurately differentiate between malignant and non-malignant lesions. Further investigations such as ultrasound-guided prostate biopsy and PSA parameters are required to accurately ascertain the nature of a prostate lesion with PI-RADS score 3.

ADVANCES IN KNOWLEDGE: An ultrasound-guided prostate biopsy in patients with PI-RADS 3 remains of paramount importance when distinguishing malignant vs non-malignant lesions. Multicentre data of MRI findings with PI-RADS 3 scores is required to yield a sample size large enough to carry out statistical analysis.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Aslam, Tsang, Bickle, et al. Multiparametric MRI prostate PI-RAD scoring in a district general hospital: correlating PI-RADS 3 results with histological findings. Br J Radiol. 2022. PMID: 34919444. doi:10.1259/bjr.20210804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。